biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > NEW CORPORATE PRESENTATION (TIMELINES)

<< Previous

Bullboard Posts

Next >>

Comment by barsaxon Nov 23, 2020 9:07am

176 Views

Post# 31951260

RE:NEW CORPORATE PRESENTATION (TIMELINES)

this presentation was created for the BIO Europe virtual conference that took place earlier...hence the October date on the presentation. From what we can see BTI has a new drug: XB3 combined with Progranulin, potentially for the treatment of Frontotemporal Dementia.

<< Previous

Bullboard Posts

Next >>

Southern Ontario mineral processing operation receives green fund support